analytical standard comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-22. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
=== Modern and contemporary === In the modern period, secularization and scientific progress shifted the focus from religious theories to naturalistic explanations, particularly starting in the late 17th century with the Age of Enlightenment. Voltaire (1694–1778), Jean-Jacques Rousseau (1712–1778), Denis Diderot (1713–1784), Adam Smith (1723–1790), and François-Jean de Chastellux (1734–1788) rejected a religious focus on otherworldly well-being, emphasizing instead the pursuit of earthly happiness through reason, empirical inquiry, and social progress.
Intentional burial, particularly with grave goods, may be one of the earliest detectable forms of religious practice since, as Philip Lieberman suggests, it may signify a "concern for the dead that transcends daily life". Evidence points to the Neanderthals as the first human species known to practice burial behavior and to intentionally bury their dead; they did so using shallow graves furnished with stone tools and animal bones. Exemplary sites include Shanidar in Iraq, Kebara Cave in Israel and Krapina in Croatia. Some scholars, however, argue that such "buried" bodies may have been disposed of for secular reasons. Though there is ongoing debate regarding the reliability of the dating method, some scholars believe the earliest human burial dates back 100,000 years. Archeological expeditions have discovered human skeletal remains stained with red ochre in the Skhul cave at Qafzeh in Israel. A variety of grave goods were present at the site, including the mandible of a wild boar in the arms of one of the skeletons. The remains of a 3-year-old child at Panga ya Saidi cave in Kenya dating to 78,000 years ago also show signs suggestive of a burial, such as the digging of a pit, laying of the body in a fetal position and intentional rapid covering of the corpse. In ancient Egypt, burial customs developed during the Predynastic period. Round graves with one pot were used in the Badarian Period (4400–3800 B.C.E.), continuing the tradition of Omari and Maadi cultures. Archeologists refer to unmarked prehistoric cemeteries using the neutral term "grave field".
Impaired fasting glycemia or impaired fasting glucose (IFG) refers to a condition in which the fasting blood glucose is elevated above what is considered normal levels but is not high enough to be classified as diabetes mellitus. It is considered a pre-diabetic state, associated with insulin resistance and increased risk of cardiovascular pathology, although of lesser risk than impaired glucose tolerance (IGT). IFG sometimes progresses to type 2 diabetes mellitus. Fasting blood glucose levels are in a continuum within a given population, with higher fasting glucose levels corresponding to a higher risk for complications caused by the high glucose levels. Some patients with impaired fasting glucose also may be diagnosed with impaired glucose tolerance, but many have normal responses to a glucose tolerance test. Fasting glucose is helpful in identifying prediabetes when positive but has a risk of false negatives. World Health Organization (WHO) criteria for impaired fasting glucose differs from the American Diabetes Association (ADA) criteria, because the normal range of glucose is defined differently by each. Fasting plasma glucose levels 100 mg/dL (5.5 mmol/L) and higher have been shown to increase complication rates significantly, however, WHO opted to keep its upper limit of normal at under 110 mg/dL for fear of causing too many people to be diagnosed as having impaired fasting glucose, whereas the ADA lowered the upper limit of normal to a fasting plasma glucose under 100 mg/dL.
Sources: en.wikipedia.org
(p) .signature (UNIX shell/Internet standard file name) (a/i) Special Interest Group (a/i) Strasbourg Illkirch-Graffenstaden Basket (French basketball club) SIGCAT – (a) Special Interest Group for CD-ROM Applications and Technology SIGINT – (p) Signals Intelligence SIGMET – (p) Significant Meteorological Information SIIT (i) Saskatchewan Indian Institute of Technologies (Canadian university) Sirindhorn International Institute of Technology (Thai university) Stateless IP/ICMP Translation algorithm SIMAC – (a) Semantic Interaction with Music Audio Contents SIMLAS – (p) Soldier Integrated Multipurpose Laser System SIMM – (a) Single In-line Memory Module SIMNET – (p) SIMulator NETwork, later SIMulation NETwork SIMNET-D - (p) SIMNET-Developmental SIMP – (a) Strongly Interacting Massive Particle SIMPLE (a) Satellite Interactive Multimedia Platform for Low-cost Earth stations (p) Savings Incentive Match Plan for Employees (as used in SIMPLE IRA) (a) Standard Interface for Multiple Platform Link Evaluation (NATO STANAG 5602) sin – (s) Sinhala language (ISO 639-2 code) SIN – (a) Social insurance number (Canada) SINCGARS – (p) SINgle Channel Ground and Airborne Radio System SIP (i) Session Initiation Protocol State Implementation Plan System Improvement Program Systematic investment plan SIPP – (a) Self-Invested Personal Pension Siri – (a) Speech Interpretation and Recognition Interface (Apple iOS software) SIRI – (a) Service Interface for Real Time Information SIRS — (a) Systemic inflammatory response syndrome SiS – (i) Silicon Integrated Systems SIS – (i) UK Secret Intelligence Service (also known as MI6) SISO (a) Simulation Interoperability Standards Organization Society of Independent Show Organizers SIW – (i) Simulation Interoperability Workshop SIYSS – (i) Stockholm International Youth Science Seminar
=== Inefficacy === Transfusion inefficacy or insufficient efficacy of a given unit(s) of blood product, while not itself a "complication" per se, can nonetheless indirectly lead to complications – in addition to causing a transfusion to fully or partly fail to achieve its clinical purpose. This can be especially significant for certain patient groups such as critical-care or neonatals. For red blood cells (RBC), by far the most commonly transfused product, poor transfusion efficacy can result from units damaged by the so-called storage lesion – a range of biochemical and biomechanical changes that occur during storage. With red cells, this can decrease viability and ability for tissue oxygenation. Although some of the biochemical changes are reversible after the blood is transfused, the biomechanical changes are less so, and rejuvenation products are not yet able to adequately reverse this phenomenon. There has been controversy about whether a given product unit's age is a factor in transfusion efficacy, specifically about whether "older" blood directly or indirectly increases risks of complications. Studies have not been consistent on answering this question, with some showing that older blood is indeed less effective but with others showing no such difference; these developments are being closely followed by hospital blood bankers – who are the physicians, typically pathologists, who collect and manage inventories of transfusable blood units.
cell surface receptor Any of a class of receptor proteins embedded within or attached to the external surface of the cell membrane, with one or more binding sites facing the extracellular environment and one or more effector sites that couple the binding of a particular ligand to an intracellular event or process. Cell surface receptors are a primary means by which environmental signals are received by the cell and transmitted across the membrane into the cell interior. Some may also bind exogenous ligands and transport them into the cell in a process known as receptor-mediated endocytosis.
Sources: en.wikipedia.org
== Conservation == Currently this species is not considered endangered or threatened by any agencies, however there are a list of potential threats that may effect their survival. Among these threats include fatal diseases such as Sponge Orange Band (SOB), environmental changes, and cyclical bleaching. Researchers are unsure what the cause of SOB is, but evidence supports the hypothesis that environmental changes, rising water temperature in particular, is responsible for the disease.
== The Sabres years (1958–1964) == The Sabres's popularity in the Central New York region prompted them to record a single ("Seaweed" (written by Ron Lauback) b/w "The McCoy" a Ventures song) which received airplay on WNDR radio in 1962 ("Seaweed" was produced by Joe Raposo at Raposo Studios). The Sabres played all the regional teen dances and even backed up Bobby Vee at The Three Rivers Inn one time for DJ Peter C. Cavenaugh The band changed its name to The Jazzmen in 1963, but split the following year. The British Invasion having rendered their Instrumental sound out of fashion. During this time Ron also graduated from Syracuse University (1964) and took a job with Bristol Laboratories (now known as Bristol-Myers Squibb).
=== Osteonecrosis of the jaw after use of Fosamax === Fosamax (alendronate) is a bisphosphonate used for the treatment of post-menopausal osteoporosis and for the prevention of skeletal problems in certain cancers. The American College of Clinical Endocrinology, the American College of Obstetricians and Gynecologists, the North American Menopause Society and the UK National Osteoporosis Guideline Group recommend alendronate and certain other bisphosphonates as first line treatments for post-menopausal osteopotosis. Long-term treatment with bisphosponates produces anti-fracture and bone mineral density effects that persist for 3–5 years after an initial 3–5 years of treatment. Alendronate reduces the risk of hip, vertebral, and wrist fractures by 35-39%. In December 2013, Merck agreed to pay a total of $27.7 million to 1,200 plaintiffs in a class action lawsuit alleging that the company's osteoporosis drug had caused them to develop osteonecrosis of the jaw. Prior to the settlement, Merck had prevailed in 3 of 5 so-called bellwether trials. Approximately 4,000 cases still await adjudication or settlement as of August 2014. There have also been thousands of lawsuits alleging that Fosamax increased the risk of thigh-bone fractures. In March 2022, Merck defeated approximately 500 lawsuits over Fosamax in New Jersey when U.S. District Judge Freda L. Wolfson ruled that the plaintiffs' lawsuit was preempted by federal law.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.